MEGI HEALTH UK

Last updated on

Visit website

NHS Problem

In the UK, cardiovascular diseases (CVDs) are a major challenge for the NHS, with 7.6 million people affected and rising due to an ageing population. These diseases account for a quarter of all UK deaths, over 160,000 annually. Hypertension, the primary modifiable risk factor, impacts 28% of UK adults, yet half receive inadequate treatment. The financial toll is substantial: healthcare costs for heart and circulatory diseases are estimated at £9 billion yearly, with the broader economic impact reaching £19 billion. These figures underscore the urgency for effective NHS strategies in managing and preventing CVDs and hypertension.

The Solution

MEGI is a transformative AI innovation reshaping cardiovascular care.

Available around the clock through messaging platforms, it offers a seamless, intuitive experience, ensuring constant support for cardiovascular patients. MEGI’s advanced AI engine skillfully processes diverse patient data, fostering enhanced early diagnoses, effective treatments, and precise risk predictions. It excels in improving patient engagement and blood pressure monitoring, significantly boosting clinical outcomes and treatment efficiency. More than a technological breakthrough, MEGI serves as a compassionate healthcare partner, empowering patients and assisting providers with a patient-centred approach, thereby redefining the standards in health technology and cardiovascular care

Impact

In its initial year, MEGI, collaborating with 37 GPs and specialised hospitals, has demonstrated significant outcomes:

  • Hypertension Management: Managed hypertension for over 5,000 patients.
  • Engagement and Retention: Averaged 27 monthly patient interactions with a one-year retention rate
  • Hypertension Diagnosis Rate in studied population: 35%
  • Treatment Time Reduction: Decreased the time to correct hypertension treatment from six months to three weeks, on a studied sample.
  • Operational Efficiency: Reduced blood pressure data collection time for healthcare providers from 15 to 4 minutes and lowered missed doctor appointments by 10%.

Additionally, MEGI’s impact on systolic pressure was monitored in two cohorts, morning and evening, encompassing over 680 patients. The results demonstrated a reduction in blood pressure within the first six months of using MEGI for both groups. These outcomes demonstrate MEGI’s effectiveness in improving patient engagement, accelerating diagnosis and treatment, and enhancing healthcare operational efficiency, along with its specific impact on managing systolic blood pressure in patients.